A major cancer drugmaker may need to buy its way out of a looming disaster
January 18, 2018 at 13:24 PM EST
Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|